CYP19A1 and lymphedema: Significant reductions in cancer pain, including aromatase inhibitor-induced arthralgia (AIA) [22,23] and lymphedema pain [24], post-mastectomy pain [25] and neuropathy pain [19,26] were reported in the included meta-analyses.